Elahere Market Report 2026

Elahere Market Overview

• The Elahere market growth in the historic period has been driven by limitations of traditional chemotherapy, high relapse rates in ovarian cancer • Market expansion is supported by increasing adoption of precision oncology, growing use of biomarker testing • Growth Driver: Rising Ovarian Cancer Incidence Fuels Growth Of The Elahere Market • Market Trend: Abbvie Secures European Approval For Elahere In Platinum-Resistant Ovarian Cancer • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Elahere Market?

Elahere (mirvetuximab soravtansine-gynx) is a targeted antibody-drug conjugate (ADC) used to treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers that express high levels of folate receptor-alpha (FRalpha). It works by delivering a cytotoxic agent directly to FR alpha-positive cancer cells, minimizing harm to healthy tissues. Approved for patients who have undergone one to three prior lines of systemic therapy, Elahere offers a personalized treatment option for managing advanced ovarian cancer. The main clinical indications in the elahere market are epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Epithelial ovarian cancer is a type of ovarian cancer that originates in the epithelial cells, which line the surface of the ovaries. The various distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, and several end-users including hospitals, homecare, specialty centers, and others.

What Is The Elahere Market Growth Forecast?

The growth in the forecast period can be attributed to increasing adoption of precision oncology, growing use of biomarker testing, expansion of adc clinical pipelines, supportive regulatory pathways for targeted drugs, rising global burden of ovarian cancer. Major trends in the forecast period include adc-based targeted oncology therapies, fralpha biomarker-based patient stratification, personalized treatment for platinum-resistant ovarian cancer, improved safety and efficacy through targeted drug delivery, rising clinical adoption of precision oncology drugs.

Global Elahere Market Segmentation

1) By Clinical Indication: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End-Users: Hospitals, Homecare, Specialty Centres, Other End-Users

What Is The Driver Of The Elahere Market?

Rising incidence of ovarian cancer is expected to propel the growth of the elahere market going forward. Ovarian cancer is a malignant disease originating in the ovaries, fallopian tubes, or peritoneum, marked by abnormal cell growth and potential spread. Ovarian cancer is attributed to genetic mutations such as BRCA1 and BRCA2, hormonal imbalances, age, family history, and environmental factors like obesity and smoking. Elahere effectively treats ovarian cancer by targeting FR alpha-positive cells and delivering a cytotoxic drug directly to the tumor, reducing harm to healthy tissue, especially in cases of platinum-resistant ovarian cancer. For instance, in 2024, the American Cancer Society, a US-based non-profit cancer advocacy organization, reported that 19,680 new cases of ovarian cancer were diagnosed in the US and 12,740 women died from the disease. Thus, the rising incidence of ovarian cancer is driving the growth of the elahere industry.

Key Players In The Global Elahere Market

Major companies operating in the elahere market are AbbVie Inc. (ImmunoGen)

Global Elahere Market Trends and Insights

The key trend in the elahere market is focusing on obtaining regulatory approvals to expand the treatment's availability for patients with platinum-resistant ovarian cancer. This move aims to strengthen its position in the market by offering a targeted therapy for a specific patient group in need of advanced treatment options. For instance, in November 2024, AbbVie, a US-based biotech company received approval from the European Commission for elahere as a treatment for adult patients with folate receptor-alpha (FR alpha) positive, platinum-resistant ovarian cancer. The approval was based on the positive results from the Phase III MIRASOL trial, which demonstrated a 35% reduction in the risk of disease progression or death compared to standard chemotherapy.

What Are Latest Mergers And Acquisitions In The Elahere Market?

In February 2024, AbbVie, a US-based biotech company, acquired ImmunoGen for $10.1 billion. With this acquisition, AbbVie aims to strengthen its oncology portfolio by gaining access to ImmunoGen's innovative antibody-drug conjugate (ADC) technology, particularly enhancing its capabilities in targeted cancer therapies such as Elahere, and further expanding its pipeline in the treatment of ovarian and other cancers, while accelerating its efforts in delivering more effective, precision-based treatments for patients. ImmunoGen is a US-based company specializing in developing antibody-drug conjugate (ADC) therapeutics, including elahere.

Regional Insights

North America was the largest region in the elahere market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Elahere Market?

The elahere market consists of sales of antibody-drug conjugates (ADCs), companion diagnostics, and supportive oncology drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Elahere Market Report 2026?

The elahere market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the elahere industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.